Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience

LakKumar Fernando,Randee Kastner,Pujitha Wickramasinghe,Asvini D. Fernando,Dulanie Gunasekera,Van Hung Nguyen,Mengya Liu,Inge LeFevre,Derek Wallace,Nicolas Folschweiller,Shibadas Biswal

DOI: https://doi.org/10.1371/journal.pntd.0012376

2024-08-24

PLoS Neglected Tropical Diseases

Abstract:Outbreaks of dengue can overburden hospital systems, drastically reducing capacity for other care. The 2017 dengue serotype 2 (DENV-2) outbreak in Sri Lanka coincided with vaccination in an ongoing phase 3 efficacy trial of a tetravalent dengue vaccine, TAK-003 (NCT02747927). Here, we present data on the efficacy of TAK-003 following two doses of the vaccine administered 3 months apart in participants aged 4–16 years in Sri Lanka. In addition, we have used the 2017 outbreak dynamics to model the potential impact of TAK-003 on virologically confirmed dengue (VCD) cases and hospitalizations during an outbreak situation. Modeling was performed using an age-structured, host-vector, spatial and stochastic transmission model, assuming 65% vaccine coverage and 30 days until initiation of vaccination. Efficacy of TAK-003 against VCD and hospitalized VCD cases was based on data against DENV-2 from the first year of the phase 3 trial. Vaccine efficacy and safety findings in Sri Lanka were in line with those of the overall trial population. The efficacy estimates in Sri Lanka up to the first 12 months after the second dose of TAK-003 were 94.7% and 95.7% against VCD and hospitalized VCD cases, respectively. Modeling of the trial data over an extended geographic area showed a substantial reduction in cases and a flattening of outbreak curves from TAK-003 use. The baseline vaccination scenario (initiation at 30 days, 65% target coverage, vaccine effective at 14 days, 70% hospitalization rate, VE of 95% for VCD and 97% for hospitalized VCD, and 47% for asymptomatic) resulted in a 69.1% reduction in VCD cases and 72.7% reduction in VCD hospitalizations compared with no vaccination. An extreme high scenario (vaccination initiated at Day 15, 80% coverage rate, baseline VE) resulted in 80.3% and 82.3% reduction in VCD and VCD hospitalizations, respectively. Vaccine performance, speed of vaccination campaign initiation, and vaccine coverage were key drivers in reducing VCD cases and hospitalizations. Overall, the study and modelling results indicate that TAK-003 has the potential of meaningful utility in dengue outbreaks in endemic areas. Dengue is a viral disease transmitted to humans by infected mosquitoes. Outbreaks of dengue occur in many tropical and subtropical countries and can place a big strain on health care services. In Sri Lanka, dengue occurs throughout the year, with outbreaks every few years. In 2017, Sri Lanka experienced a large dengue outbreak caused by dengue virus serotype 2. By chance, a clinical trial of a dengue vaccine (TAK-003) was taking place at the same time, which allowed us to look at how well the vaccine could work to control an outbreak. Because all trial sites were in a small region of Sri Lanka, we used a model to look at the vaccine's potential impact over a wider area. Data from the clinical trial showed that the vaccine lowered the risk of symptomatic dengue infection and the risk of hospitalization owing to dengue. In addition, using epidemiological data from Sri Lanka at the time of the outbreak, the model showed that vaccination would be linked to a reduction in dengue cases and related hospitalizations compared with no vaccination, and would "flatten the curve" of the outbreak. Overall, our study shows that TAK-003 could be useful in controlling a dengue outbreak.

tropical medicine,parasitology